Cryo-Cell International Inc (CCEL) FinancialsCCELCryo-Cell International Inc

Cryo-Cell International Inc (CCEL) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Processing and storage fees, accounting for 97.8% of total sales, equivalent to $7.65M. Other significant revenue streams include Public banking revenue and Product revenue. Understanding this composition is critical for investors evaluating how CCEL navigates market cycles within the Healthcare Facilities & Services industry.

Evaluating the bottom line, Cryo-Cell International Inc maintains a gross margin of 77.02%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 28.04%, while the net margin is 16.24%. These profitability ratios, combined with a Return on Equity (ROE) of N/A, provide a clear picture of how effectively CCEL converts its operational activities into shareholder value.

In the context of the broader market, CCEL competes directly with industry leaders such as PTLE and SWVL. With a market capitalization of $39.41M, it holds a significant position in the sector. When comparing efficiency, CCEL's gross margin of 77.02% stands against PTLE's 1.27% and SWVL's 18.16%. Such benchmarking helps identify whether Cryo-Cell International Inc is trading at a premium or discount relative to its financial performance.

Cryo-Cell's recent financial performance shows a decline in revenue, with Q1 2026 revenue at $7.68 million, down 3.6% year-over-year. However, it reported a net income of $1,270,490 in Q3 2026, indicating some recovery. The gross margin is relatively strong at 77.02%, but the overall financial health remains fragile with a current ratio of 0.86.